Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus (itch).

News
Trevi Therapeutics Announces Initiation of a Pivotal Study of Nalbuphine ER in Prurigo Nodularis
3/11/2015
Study will enroll 60 patients in the United States and Europe